Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
A phase 3 trial of Lurbinectedin, FOLFIRI, Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.
Overview
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC is a phase 3 interventional study registered as NCT06496048 by Luye Pharma Group Ltd., with 180 participants planned, started 2024-09-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: Lurbinectedin, Irinotecan, Lurbinectedin, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Shares Luye Pharma Group, Topotecan, Small-cell lung cancer.
- TrialATLANTIS
Shares Lurbinectedin, Topotecan, Small-cell lung cancer.
- TrialIDeate-Lung02
Shares Lurbinectedin, Topotecan, Small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Shares Lurbinectedin, Topotecan, Small-cell lung cancer.
- TrialPharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Shares Topotecan, Small-cell lung cancer.
- TrialA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Shares Topotecan, Small-cell lung cancer.
- TrialA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Shares Lurbinectedin, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Shares Topotecan, Small-cell lung cancer.